<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529424</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 304801-CS2</org_study_id>
    <nct_id>NCT01529424</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS
      ApoC-III Rx vs. Placebo on fasting total apoC-III levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VLDL apoC-III</measure>
    <time_frame>92 Days</time_frame>
    <description>The effect of treatment with ISIS ApoC-III Rx or Placebo on fasting total apoC-III levels.</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-extensive PK/non post-prandial</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Extensive PK</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Post-prandial assessment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable dose of fibrate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fredrickson Type 1 dyslipidemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS apoC-III Rx</intervention_name>
    <description>Dose 1</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS apoC-III Rx</intervention_name>
    <description>Dose 2</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS apoC-III Rx</intervention_name>
    <description>Dose 3</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose 1</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose 2</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Dose 3</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2a</arm_group_label>
    <arm_group_label>Group 2b</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hypertriglyceridemia

        Exclusion Criteria:

          -  HbA1c &gt;/=9.0%, type 1 diabetes, or history of outpatient insulin use for more than 2
             weeks in the last year

          -  Body mass index (BMI) &gt;40 kg/m2

          -  History of bariatric surgery or currently on weight loss drugs

          -  Use of oral contraceptives or hormone replacement therapy or statins unless stable for
             3 months prior to dosing

          -  Group 1 and 2 patients: Use of systemic corticosteroids, fibrates, niacin, fish oil or
             other products containing omega-3 fatty acids within 6 weeks of dosing. Group 3
             patients: unable to discontinue use of systemic corticosteroids at least 6 weeks prior
             to dosing ; use of niacin, fish oil, or other products containing omega-3 fatty acids
             unless on a stable well controlled dose for at least 30 days prior to screening that
             is not anticipated to change during the study period. Group 4 patients: unable to
             discontinue use of systemic corticosteroids at least 6 weeks prior to dosing; use of
             fibrates niacin, fish oil, or other products containing omega-3 fatty acids unless on
             a stable well controlled dose for at least 30 days prior to screening that is not
             anticipated to change during the study period.

          -  Use of topical corticosteroids, anticoagulants, or drugs or dietary supplements with
             potential lipid-altering effects unless dose is stable and well controlled for 30 days
             prior to dosing

          -  Any Screening laboratory values that are out of allowed reference ranges

          -  Inability to comply with protocol or study procedures

          -  Any other significant illness or condition that may adversely affect the subjects
             participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farmville Internal Medicine</name>
      <address>
        <city>Farmville</city>
        <state>North Carolina</state>
        <zip>27828</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark R. Cervi</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians East, Quadrangle Medical Specialists</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina East Family Medicine</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Physicians</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natalie A Doyle, MD PA</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isis Investigational site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <disposition_first_submitted>June 14, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>June 14, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 16, 2016</disposition_first_posted>
  <last_update_submitted>June 14, 2016</last_update_submitted>
  <last_update_submitted_qc>June 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

